CD47 and neoplasm: The study showed that HX009 blocked both CD47/SIRPα and PD-1/PDL-1 interactions, and interacted with CD47 on tumor cells and PD1 on T cells to help present tumor antigens to T cells, resulting in activation of the innate and acquired immune responses.